Connecting the Dots: Integrating Nonsteroidal MRAs in Heart Failure and CKD Care event time Sunday, November 8th @ 9:00 PM ART | 2 hrs (+...)

Connecting the Dots: Integrating Nonsteroidal MRAs in Heart Failure and CKD Care event time Sunday, November 8th @ 9:00 PM ART | 2 hrs event location McCormick Place, Chicago, Illinois, United States event specialty Cardiology, Diabetes & Endocrinology, Internal Medicine https://www.medscapelive.com/?_gl=1*vaqkn*_gcl_aw*R0NMLjE3OTQxNTA2NTEuQ2p3S0NBaUEyTURYQmhCVUVpd0FELVlCLXd1b01GR3dXT21oQVlPX1loTFBUYVNTZHBWUDRLUjFwZkt5NGhBdEhVbURyUUdrcFR0NUh4b0NFaWNRQXZEX0J3RQ..*_gcl_au*MTA2Mzc5MDEwMS4xNzg5ODMwNjQxLjE3NTgwOTUyMDguMTc5NDIzODgwMC4xNzk0MjM4Nzk5Ljc0MjUxOTQ1MC4xNzk0MjMxMTY2LjE3OTQyMzg3OTk.

Emerging Psychedelic Therapies for Depression Charles DeBattista, MD (videos)

https://reference.medscape.com/viewarticle/major-depressive-disorder-emerging-psychedelic-therapies-2026a1000wku Many patients with depression do not find symptom relief from the current range of approved treatments. Psychedelic therapies are emerging as an option to address this unmet need, as outlined by Dr Charles DeBattista of Stanford University. Dr DeBattista explains that psilocybin and LSD were studied in depression in the 1950s and 1960s. Recent interest has led to more rigorous examination of their benefits and the potential for approval in 2027. https://www.medscape.com/video?_gl=1*1cehy2z*_gcl_aw*R0NMLjE3OTQxNTA2NTEuQ2p3S0NBaUEyTURYQmhCVUVpd0FELVlCLXd1b01GR3dXT21oQVlPX1loTFBUYVNTZHBWUDRLUjFwZkt5NGhBdEhVbURyUUdrcFR0NUh4b0NFaWNRQXZEX0J3RQ..*_gcl_au*MTA2Mzc5MDEwMS4xNzg5ODMwNjQxLjE3NTgwOTUyMDguMTc5NDIzODgwMC4xNzk0MjM4Nzk5Ljc0MjUxOTQ1MC4xNzk0MjMxMTY2LjE3OTQyMzg3OTk.

Targeting Glucagon in the Treatment of Obesity: Insights From EASD 2026 Kirsi H. Pietiläinen, MD, PhD (videos)

https://reference.medscape.com/viewarticle/easd-2026-glucagon-updates-obesity-management-2026a10012gq Adding glucagon receptor agonists to GLP-1-based medications may prove beneficial in the treatment of overweight and obesity. Prof Kirsi H. Pietiläinen of the University of Helsinki in Helsinki, Finland, reviews four studies presented at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting that addressed glucagon receptor targeting. In an MRI substudy of the phase 3 SYNCHRONIZE-1 trial, the dual glucagon/GLP-1 receptor agonist survodutide 6 mg produced 18% weight loss compared to 6.9% with placebo. Survodutide also resulted in substantial reductions in metabolically harmful fat with subcutaneous, visceral, and liver fat reductions of about 28%, 34%, and 63%, respectively.

Top Picks From Madrid 2026: Experts’ Highlights on Breast Cancer Advances Authors: Wolfgang Janni, MD, PhD; Paolo Tarantino, MD, PhD; Valentina Guarneri, MD, PhD

https://www.medscape.org/viewarticle/top-picks-madrid-2026-experts-highlights-breast-cancer-2026a100164e?page=1

Advancing Women's Health: Key Priorities and Interventions for Enhanced Outcomes

Advancing Women's Health: Key Priorities and Interventions for Enhanced Outcomes This collection page features educational programs for healthcare practitioners to treat, diagnose, and manage issues facing women and girls. Timely education and associated data on key health-related topics are important to improve health outcomes, diagnosis, decision-making, prescription medication, and testing to allow for shared decision-making. Topics include syphilis (including congenital syphilis), menopause, sarcopenia, and breast cancer. https://www.medscape.org/advances/advancing-womens-health-2026a1000fto

PrecIsion Oncology: Navigating EvidEnce for Real-world impact (PIONEER)

https://www.medscape.org/advances/oncology-pioneer-2025a1000ih5?src=ban_driv_260303_mscpedu_447301.01_ace Join PIONEER's mission to advance precision oncology through evidence-based education and expert guidance. Our platform provides access to a wide range of educational activities in personalized cancer care. From biomarker identification to therapeutic optimization, explore how precision medicine is transforming treatment paradigms. Our comprehensive resources offer practical guidance for implementing cutting-edge approaches that deliver meaningful impact for both patients and healthcare systems.

Conversations on Pain: Determining the Causes, Making a Plan, and Considering Nonopioid Analgesics Authors: Jeff Gudin, MD; Timothy J. Atkinson, PharmD, CPE; Antje Barreveld, MD; Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS; Steven P. Stanos, DO

https://www.medscape.org/viewarticle/conversations-pain-determining-causes-making-plan-and-2025a1000wsc?page=1 Supported by an independent educational grant from Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/ resources/docs/list_of_RPC_companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).